Cochrane · systematic review · CD005449
Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus
Valentine, N, Van de Laar, FA, van Driel, ML · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
3
Included studies
NR
No studies 3 · 42.9%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 57.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: patients with type 2 diabetes mellitus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (ticlopidine vs placebo) | RR 1.29 [0.71, 2.32] | 1 study · 335 participants | Moderate Downgraded: imprecision |
Vascular mortality (ticlopidine vs placebo) | RR 0.94 [0.47, 1.88] | 1 study · 335 participants | Moderate Downgraded: imprecision |
Myocardial infarction (fatal and non‐fatal) (ticlopidine vs placebo) | RR 0.78 [0.39, 1.57] | 1 study · 335 participants | Moderate Downgraded: imprecision |
Stroke (fatal and non‐fatal) (a. ticlopidine vs aspirin) (b. clopidogrel vs aspirin & dipyramidole) | RR 0.56 [0.37, 0.94] | 1 study · 597 participants | Moderate Downgraded: imprecision |
Health‐related quality of life | no estimate extracted | NR | No studies |
Adverse effects | no estimate extracted | NR | No studies |
Costs | no estimate extracted | NR | No studies |